DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing

According to an SEC filing dated February 17, 2026, DAFNA Capital Management LLC reduced its involvement successful iShares Biotechnology ETF (NASDAQ:IBB) by 34,405 shares during the 4th fourth of 2025. The fund’s quarter-end IBB presumption worth decreased by $3.31 million, a fig that factored successful some stock income and terms movement.

Following the sale, iShares Biotechnology ETF is comprised 2.67% of DAFNA Capital’s 13F reportable assets nether management.

Top 5 holdings aft the filing:

• NASDAQ:RVMD: $48.15 cardinal (11.3% of AUM)

• NYSEMKT:XBI: $41.03 cardinal (9.7% of AUM)

• NYSEMKT:STXS: $31.47 cardinal (7.4% of AUM)

• NASDAQ:ATRC: $23.63 cardinal (5.6% of AUM)

• NASDAQ:CYTK: $23.57 cardinal (5.5% of AUM)

As of February 17, 2026, shares of IBB were priced astatine $174.02, up 27.2% implicit the past year, with a one-year alpha of 15.84 percent points versus the S&P 500.

iShares Biotechnology ETF provides investors with targeted vulnerability to the biotechnology assemblage by tracking a specialized manufacture index. The ETF way s the show of the NASDAQ Biotechnology Index by investing astatine slightest 80% of assets successful scale components and substantially identical securities. It chiefly invests successful biotechnology and pharmaceutical equities, with vulnerability diversified crossed starring manufacture constituents.

The money employs a passive concern approach, allocating the bulk of assets to companies wrong the NASDAQ Biotechnology Index and maintaining flexibility to usage derivatives for portfolio management. It is structured arsenic a non-diversified ETF, with a absorption connected businesslike scale replication and liquidity management.

Its standard and liquidity connection organization investors businesslike entree to a wide array of biotechnology equities, supporting portfolio diversification and sector-specific strategies.

The iShares Biotechnology ETF (IBB) offers vulnerability to the biotech assemblage done a market-cap-weighted portfolio focused connected large, commercial-stage companies with approved products and established pipelines. This attack emphasizes manufacture leaders and reduces reliance connected early-stage and higher-risk firms.

IBB’s show is driven chiefly by large-cap biotech earnings, merchandise results, pipeline progress, and regulatory decisions. Since the money is top-heavy, a tiny fig of companies relationship for astir returns. Although established businesses tin trim volatility compared to equal-weighted biotech funds, the assemblage remains delicate to involvement rates and capitalist hazard appetite, which impact the valuation of growth-oriented healthcare stocks.